Quick Answer
CRISPR Therapeutics AG reported Revenue From Contract With Customer Excluding Assessed Tax of $3.51 million for the year ending 2025.
- CRISPR Therapeutics AG showed a decrease of -90.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), CRISPR Therapeutics AG's Revenue From Contract With Customer Excluding Assessed Tax has grown by 12.4%.
- Historical annual values: Fiscal year 2025: $3.51 million | Fiscal year 2024: $37.31 million | Fiscal year 2023: $371.21 million | Fiscal year 2022: $1.20 million | Fiscal year 2021: $914.96 million | Fiscal year 2020: $719.0 thousand | Fiscal year 2019: $289.59 million | Fiscal year 2018: $3.12 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: